Study of Blood and Eye Scan Markers in Adults With Diabetic Macular Edema Receiving Anti-VEGF or Dexamethasone Implant Treatment

What this Trial Is About

This research aims to investigate the relationship between blood serum biomarkers and how patients with diabetic macular edema DME respond to treatments with anti-VEGF or dexamethasone implants. The study compares these treatments to a group of patients who have not previously received treatment for DME. Researchers will also assess eye imaging markers using OCT scans to better understand this condition. Participants will be divided into three groups those receiving anti-VEGF treatment, those receiving dexamethasone implants, and those who are treatment-naive. Blood samples will be taken at the start for all groups, and again after four weeks for the untreated group. OCT scans of the retina and choroid will be performed at baseline and after four weeks to evaluate specific imaging markers related to DME. During the study, participants will undergo blood tests to measure levels of several biomarkers including VEGF, IL-6, IL-8, MCP-1, Ang-2, PlGF, TNF-a, and ICAM-1. OCT scans will be analyzed for retinal layer disruptions and fluid presence. Researchers will classify participants based on their response to treatment and monitor changes over the four-week period. The total participation time varies based on group and treatment status.

Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant